

### **Investor Presentation** March 2023

### Safe harbor

This presentation does not constitute an offer or invitation for the sale or purchase of securities and has been prepared solely for informational purposes. This presentation is a summary of information contained in our public filings filed with the Securities and Exchange Commission (SEC), which public filings are expressly incorporated herein by reference (see <u>http://ir.healthequity.com/</u>), and other publicly available information. Readers are encouraged to review our public filings for further information.

This presentation contains "forward-looking" statements that are based on our management's beliefs and assumptions and on information currently available to management. These forward-looking statements include, without limitation, statements regarding our industry, business strategy, plans, goals and expectations concerning our market position, product expansion, future operations, margins, profitability, future efficiencies, capital expenditures, liquidity and capital resources and other financial and operating information. When used in this discussion, the words "may," "believes," "intends," "seeks," "anticipates," "plans," "estimates," "expects," "should," "assumes," "continues," "could," "will," "future" and the negative of these or similar terms and phrases are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements represent our management's beliefs and assumptions only as of the date of this presentation. Our actual future results may be materially different from what we expect. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. Readers are encouraged to review our public filings with the SEC for further disclosure of other factors that could cause actual results to differ materially from those indicated in any forward-looking statements included herein.

This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates.

This presentation includes certain non-GAAP financial measures as defined by SEC rules. As required by Regulation G, we have provided a reconciliation of those measures to the most directly comparable GAAP measures, which is available in our public filings.

No part of this presentation may be copied, recorded, or rebroadcast in any form.

### **Market leader**





Total accounts





HSA Assets



120K+

Employer clients



#1


HSA Administrator - Devenir

Note – HealthEquity HSAs, HSA Assets and other metrics as of January 31, 2023, except Devenir ranking is as of the Devenir June 30, 2022 report.



# Outpacing a secular growth market


FY23 sales results



Market growth estimate from proprietary research June 2021. Market data from Devenir Mid-year reports 2017-2022.

Sales results data is as of January 31, 2023.

### **HSA openings**



HSA Sales for HealthEquity fiscal year ending January 31, 2023. Figures exclude HSAs from previously announced acquisitions


### Value chain from channel partner to member


Asset growth driven by engagement programs

+90% Increased contribution rate

Strong channel partners

**200+** Network partners





Asset growth metric refers to increased contribution rate of HSA members enrolled in Engage 360 program. MaxEnroll metric refers to the number of total employees reached compared to prior year without MaxEnroll.

### Expanding channel partnerships drive sales; client relationships

**HealthEquity** 

**75%** Sales originate with channel partners

+50% Greater win rate with channel partners Further

+8 Health Plan Partnerships

+\$1.9B

Assets



Partnerships are extremely important to us as we realize we can't do it all.

Corey Tauer BCBS Minnesota

"

Data as of November 2022

Further data reflects date of acquisition

# HSAs build financial stability and resilience for the entire workforce

#### Ð

#### **Plan Design**

Case Study

Contribution Matching Tiered Contribution

#### Engagement

Tailored resources Comprehensive messaging



### 1 in 3

Colleagues chose the HSA

**\$1,139** Est tax savings per colleague

#### **37%** Of colleagues in lowest salary band elected HSA



This was a compassionate, kind, thoughtful design that we really hoped would be looked to as an example of how a health plan could be structured.

Michele Proscia, Pfizer



### **Deeper adoption** by existing clients

#### **Best Practice**

#### **Education at Scale**



New HSA adoption for clients using bestpractice program

**4**x

Non-HSA members included YoY



Clients using group education

**73k** 

Visits from employers to the self-serve toolkit



Self-serve education





Date - Date HSA-qualified health plan options

consumer choice plan #3

Focus on

savings



### Ongoing HSA member engagement drives positive financial outcomes

#### **Engage 360 vs Unenrolled Clients**

+90%

higher increase in amount contributed

+10% more likely to begin contributing


members took action to personalize

368k

Q1 FY' 22, all numbers are FYTD, Baseline set of avg contributions made in Feb & Mar 2021 versus Dec 2021 contributions

HealthEquity YoY balance growth as of October 31, 2022, and industry growth from Devenir Mid-year report June 30, 2022

#### HSA Avg. Balance Change YoY



### A broader, connected ecosystem, enabled by data and integrations

#### **Technology Investments**



Privacy & Security



Connectivity



Cloud Data Platform



### **Collaboration for the member**



- Immediate reimbursement
- Easier claim submission
- Lower administrative cost



#### **Embedded Banking**


- Instant card availability
- Payment deferral options
- Easier check-in with provider

#### **Mobile Experience**

- Timely reminders
- Real-time updates
- Anytime access to help

Janice Harper Member since 2019

# Improving yields on HSA cash



HQY yield					
FY 2019	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024 (outlook)
2.15%	2.44%	2.06%	1.75%	1.90%	~2.30%

#### 7

- Enhanced Rates adoption
- Increasing bank demand
- Diversified partner base
- Laddered portfolio


HealthEquity yield on HSA cash estimated for FY24 as of March 21, 2023.

### **Capital structure**

(\$ in millions)	January 31, 2023	January 31, 2022
Cash, cash equivalents & marketable securities	\$254	\$225
Long-term debt, net of debt issuance costs (\$1B available LOC)	\$925	\$931
Debt to Adjusted EBITDA leverage	2.5x	3.0x

### **HSA Key metrics**

**HSAs** (000s)



#### 777K net increase YoY

#### 11% growth YoY

NOTE: HSA and HSA Asset balances as of January 31 in each year

Historic performance depicted is not necessarily indicative of past and future performance.

For more information, see our Company's public filings with the Securities and Exchange Commission

HSA Assets (\$M)		Total	Total Accounts (000s)			
Invested ass Cash assets				•	0.014	
		\$22,146	HS	A	<b>8.0M</b>	
	\$19,618	\$7,947	FS	4	3.3M	
\$14,335	\$6,675	ψι,3+ι	HR	Α	1.9M	
\$4,216			СО	BRA	0.5M	
\$10,119	\$12,943	\$14,199	Cor	mmuter	0.6M 0.6M	
FY2021	FY2022	FY2023	Our	ier	U.OIVI	

#### **\$2.5B** net increase YoY

**13%** total HSA asset growth YOY

10% cash / 19% investment growth YoY

### **Fiscal third quarter financial results**

Revenue (\$M)



15% Q4 revenue growth YoY

2% Q4 Service Revenue growth YoY

44% Q4 Custodial Revenue growth YoY

**10%** Q4 Interchange Revenue growth YoY

Adjusted EBITDA<sup>(1)</sup> (\$M)



**31%** Adjusted EBITDA margin Q4FY23

NOTE: Historic performance depicted is not necessarily indicative of past and future performance. For more information, see our Company's public filings with the Securities and Exchange Commission (1) See press release on March 21, 2023, for a reconciliation of net income, the most comparable GAAP measure, to Non-GAAP Adjusted EBITDA.

### Guidance

Business	Outlook
Dusiness	Outiour

HealthEquity fiscal year ending January 31, 2024

<b>Guidance as of:</b> (\$ in millions, except per share)	March 21, 2023
Revenue	\$960 - \$975
Non-GAAP net income**	\$152 - \$163
Non-GAAP Net income per diluted share**	\$1.74 - \$1.87
Adjusted EBITDA <sup>**</sup>	\$320 - \$335

\*Guidance issued in press release dated March 21, 2023. We do not undertake to update this guidance, which speaks only as of the date given.

\*\*See press release on March 21, 2023, for a reconciliation of net income, the most comparable GAAP measure, to Non-GAAP Net Income, Non-GAAP EPS and Adjusted EBITDA.

### **Foundation of promises kept**





Growth



Visibility



Profitability



**Sustainability** 

30%

5-yr revenue CAGR<sup>1</sup>

35

Consecutive quarters beating adjusted EBITDA consesus<sup>2</sup> 26%

5-yr Adjusted EBITDA CAGR<sup>1</sup> +10

Years increased market share<sup>3</sup>

1- HealthEquity data based on FY23 LTM changes from fiscal years 2018 to 2023

2- Based on FactSet consensus during quarterly reporting between fiscal years 2014 to 2023

3- Based on Devenir Research HSA reports December 2010 to December 2021

## HealthEquity Investor Day July 11, 2023 Draper, UT

HealthEquity®